Oncology Business Management

Dr. David Gandara, from University of California, Davis Comprehensive Cancer Center, discusses using the multiplexing assay for patients with non-small cell lung cancer

Tivantinib has demonstrated statistically significant improvements in time to progression and overall survival versus placebo among patients with unresectable hepatocellular carcinoma.

Dr. Paul J. Hesketh, from Lahey Clinic Medical Center, on Developing Guidelines and Protocols

Research presented at ASCO 2012 examined the expanded use of sipuleucel-T, as well as methods to determine which patients might benefit the most from the therapy.

Dr. Michael S. Ewer, from The University of Texas MD Anderson Cancer Center, on Supportive Care

The FDA has approved everolimus for treating patients with hormone receptor-positive, HER2 negative breast cancer, when given in combination with the aromatase inhibitor exemestane.

Nurse staffing varies from institution to institution, depending on many factors, both internal and external. To gain a better understanding of nurse staffing, ratios of nurses to patients, and productivity, a survey was sent to ONS members.

Health plans continue to seek methods to curtail cancer costs.

Prior approval improves chances of being reimbursed, increases practice costs, and can delay treatment.

Case-based discussion on sequencing prostate cancer therapies for a 72-year-old man with a metastatic adenocarcinoma with small-cell components, a PSA score of 80, and a Gleason score of 10.

Leaders in the oncology care and research communities largely applauded the US Supreme Court ruling Thursday that upholds the Affordable Care Act.

A chronic shortage of the most commonly used taxane for ovarian cancer would add almost $9 million a month to the cost of care if half of newly diagnosed cases were affected.

As we head into the sweltering days of summer, physicians-and urologists in particular-face a series of challenges that can potentially impact the way we practice and how we manage our patients.

Dr. Richard Schilsky, from the University of Chicago, Summarizes the Recent Oncology Drug Shortage.

2011 survey finds 25% of adults experienced a gap in health insurance last year.

Dr. Charles Ryan, from UCSF Helen Diller Family Comprehensive Cancer Center, Discusses Sequencing Castration-Resistant Prostate Cancer Therapies.

Economic pressures are forcing many oncologists to leave small private practices for larger institutional organizations.

One of my teachers in medical school was fond of saying, "Internal medicine isn't sexy." Hematology/ oncology is no exception to this rule. Certainly, it is not as glamorous as cardiology or as hands-on as gastroenterology.

We all have to balance competing demands on our time. But as an academic oncologist, I have to keep a foot in 2 worlds, research and clinical, while still keeping my balance.

Checking in with patients can bring positive results, since oncology nurses are able to offer interventions for most symptoms of cancer treatment. Includes an in-depth look at telephone triage.

Three case studies focused on how best to sequence therapy in prostate cancer were presented by Daniel P. Petrylak, MD, and discussed by a panel that included Robert Dreicer, MD, and Oliver Sartor, MD.

An interview with ASCO President Michael P. Link, MD, discussing the impact of oncology drug shortages.

Drug manufacturers are working with the FDA to report anticipated shortages earlier and ensure alternative sources of needed drugs are available.

Dr. Leonard Gomella, form the Jefferson Kimmel Cancer Center, on the Impact of the New USPSTF PSA Rating.